Identifying breast cancer patients who can be spared chemotherapy, evidence from recent studies

The Oncotype DX® 21-gene Recurrence Score® result stratifies patients with breast cancer into low-, intermediate- and high-risk groups that correspond to the likelihood of recurrence after the initial diagnosis. At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Oleg Gluz, MD, from the West German Study Group, Mönchengladbach, Germany, discusses the evidence of the predictive value of the Recurrence Score® result to guide decision making for adjuvant chemotherapy.

This content is supported by Genomic Health, Inc.

Year of Production:
Running Time:
Color/Sound:

2016
2:01
Color/Sound

Comments are closed.